Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 65

Results For "ABLE"

5833 News Found

Addex spin-out Neurosterix launches Phase 1 trial for novel schizophrenia drug
Clinical Trials | January 09, 2026

Addex spin-out Neurosterix launches Phase 1 trial for novel schizophrenia drug

NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor


IMCD opens beauty, personal Care laboratory in California
R&D | January 09, 2026

IMCD opens beauty, personal Care laboratory in California

The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions


Alkem launches innovative hair growth support therapy kit
News | January 09, 2026

Alkem launches innovative hair growth support therapy kit

The supplements are made using only vegetarian-sourced ingredients


GSK secures European nod for easier-to-use Shingrix prefilled syringe
News | January 09, 2026

GSK secures European nod for easier-to-use Shingrix prefilled syringe

The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration


WHO unveils updated HIV guidelines to boost treatment & save lives
News | January 09, 2026

WHO unveils updated HIV guidelines to boost treatment & save lives

The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency


Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy
News | January 09, 2026

Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy

The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases


Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer
Clinical Trials | January 09, 2026

Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer

The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2


Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
News | January 09, 2026

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial